Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has provided an announcement.
Venus Medtech (Hangzhou) Inc. reported its unaudited consolidated interim results for the first half of 2025, showing a decrease in revenue by 18.9% compared to the same period in 2024. Despite a reduction in losses before tax by 35.1%, the company continues to face challenges with a loss of RMB 134,772,000 for the period, highlighting ongoing financial pressures and the need for strategic adjustments to improve profitability.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing and commercializing innovative medical devices, particularly in the cardiovascular sector.
Average Trading Volume: 5,359,860
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.88B
For detailed information about 2500 stock, go to TipRanks’ Stock Analysis page.